Drugs / Tc99m-MAA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04105283 | Aug 2020 → Jun 2024 | lung cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02050724 | Nov 2013 → Dec 2016 | bronchial neoplasm, pulmonary coin lesion | Cantonal Hospital of St. Gallen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tc-99m MAA | “with subsequent injection of 25-30 MBq (effective: 7-14 MBq) Tc-99m MAA (Macro Albumin Aggregate).” PMID 27207315 ↗ May 2016 |
| Known as | Macro Albumin Aggregate | “with subsequent injection of 25-30 MBq (effective: 7-14 MBq) Tc-99m MAA (Macro Albumin Aggregate).” PMID 27207315 ↗ May 2016 |
| Modality | Diagnostic / imaging agent | “a radiotracer called Tc99m-MAA” NCT04105283 ↗ |
| Route | Other | “via the bronchial artery or branches thereof” NCT04105283 ↗ |